ResMed Chairman Emeritus Peter Farrell Sells Shares Under 10b5-1 Plan

An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.

ResMed Chairman emeritus and director Peter C. Farrell has reported the sale of 2,000 shares of ResMed common stock at a price of $251.31 per share, leaving him with beneficial ownership of 64,773 shares. The transaction, dated 4 February 2026, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 12 August 2025, indicating the sale was part of a structured diversification or liquidity strategy rather than a discretionary market-timed trade, and offering stakeholders transparency into insider dealings.

The disclosed sale is relatively modest in the context of Farrell’s remaining holdings and does not signal a significant reduction in his equity stake. For investors and corporate governance observers, the filing underscores ongoing insider ownership at the board level while highlighting the use of Rule 10b5-1 plans to manage potential conflicts of interest and perceptions around trading by senior insiders.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a medical technology company specializing in devices and software for the diagnosis, treatment, and management of sleep apnea and other chronic respiratory conditions. The company focuses on home-based and clinical solutions that support patients with sleep-disordered breathing, chronic obstructive pulmonary disease, and related conditions across global healthcare markets.

Average Trading Volume: 1,047,790

Technical Sentiment Signal: Buy

Current Market Cap: A$56.42B

For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.